Remy B. Verheijen

AstraZeneca Pharmaceuticals - United Kingdom

Cambridge

United Kingdom

SCHOLARLY PAPERS

2

DOWNLOADS

59

SSRN CITATIONS

1

CROSSREF CITATIONS

0

Scholarly Papers (2)

1.

A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors

Number of pages: 222 Posted: 03 Oct 2019
Harvard University - Department of Medicine, National Cancer Center, Korea, Sungkyunkwan University - Division of Hematology-Oncology, Yonsei University - Yonsei Cancer Center, Memorial Sloan Kettering Cancer Center, University of Ulsan - Department of Oncology, National Taiwan University - Department of Oncology, Seoul National University - Department of Internal Medicine, National Cheng Kung University - Department of Internal Medicine, Maria Sk?odowska-Curie Institute of Oncology, BioEq, LLC, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom and Harvard University - Department of Thoracic Oncology
Downloads 35 (497,606)
Citation 1

Abstract:

Loading...

2.

A Phase 1b Study of Savolitinib Plus Gefitinib for Patients with EGFR-Mutated MET-Amplified Advanced Non-Small-Cell Lung Cancer

Number of pages: 40 Posted: 20 Jan 2020
Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Beijing Cancer Hospital, Nanjing Medical University - Department of Oncology, Fudan University, Harbin Medical University - Cancer Hospital, Guangzhou Medical University - First Affiliated Hospital, Jilin University (JLU) - First Affiliated Hospital, Government of the People's Republic of China - 307th Hospital, Central South University - Hunan Cancer Hospital, Tongji University - Shanghai Pulmonary Hospital, Soochow University - First Affiliated Hospital, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United States, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - United Kingdom, AstraZeneca Pharmaceuticals - China and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 24 (557,855)

Abstract:

Loading...

Savolitinib; Gefitinib; EGFR-TKI; NSCLC; China; MET